Skip to content

MAZE MAZE MA — Tax Credit Carryforward Amount

Other geography segments

CA
$10.87M

Similar metrics at other companies

Beam Therapeutics logo
BEAMMA — Tax Credit Carryforward Amount
$36.4M+11.3%
Achieve Life Sciences logo
ACHVCA — Tax Credit Carryforward Amount
$1.9M-29.6%
Novanta logo
NOVTUS — Tax Credit Carryforward Amount
$1.5M
Amylyx Pharmaceuticals, Inc. logo
AMLXMA — Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
$201M+67.6%
Novanta logo
NOVTUS State Credits — Tax Credit Carryforward Amount
$2.7M+3.8%
Nuvation Bio logo
NUVBR&D credit carryforward
$23.38M+20.6%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.5B+205%
Enterprise value$1.36B
P/S

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:TaxCreditCarryforwardAmount.

The official record: MAZE’s 10-K, filed March 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's ma — tax credit carryforward amount.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's MA — tax credit carryforward amount?
MAZE (MAZE) reported MA — tax credit carryforward amount of $235K in Q4 2025.
What does MA — tax credit carryforward amount mean?
This represents the total value of accumulated tax credits that a company can apply to reduce future tax liabilities. These credits are typically generated from research and development activities or prior operating losses and serve as a significant non-cash asset for clinical-stage biopharmaceutical companies. Investors monitor this balance to assess the potential for future tax shielding as the company moves toward commercialization and profitability.